CN113750140A - 白芍总苷在制备治疗类风湿关节炎药物中的应用 - Google Patents
白芍总苷在制备治疗类风湿关节炎药物中的应用 Download PDFInfo
- Publication number
- CN113750140A CN113750140A CN202110398135.8A CN202110398135A CN113750140A CN 113750140 A CN113750140 A CN 113750140A CN 202110398135 A CN202110398135 A CN 202110398135A CN 113750140 A CN113750140 A CN 113750140A
- Authority
- CN
- China
- Prior art keywords
- paeony
- eluting
- total glucosides
- radix paeoniae
- paeoniae alba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000006484 Paeonia officinalis Nutrition 0.000 title claims abstract description 46
- 241001106477 Paeoniaceae Species 0.000 title claims abstract description 46
- 229930182478 glucoside Natural products 0.000 title claims abstract description 35
- 150000008131 glucosides Chemical class 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000583 acetic acid Drugs 0.000 claims abstract description 18
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 18
- 238000004440 column chromatography Methods 0.000 claims abstract description 13
- 239000003480 eluent Substances 0.000 claims abstract description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000010298 pulverizing process Methods 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 9
- 229920005989 resin Polymers 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 238000011068 loading method Methods 0.000 claims abstract description 5
- 238000001179 sorption measurement Methods 0.000 claims abstract description 5
- 238000000227 grinding Methods 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 239000011505 plaster Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 5
- 244000236658 Paeonia lactiflora Species 0.000 description 4
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 description 2
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 2
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 2
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- NLSMPWTZYGSAEU-CYUNEVMDSA-N (2s,3r,4s,5s,6r)-2-[7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromenylium-5-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 NLSMPWTZYGSAEU-CYUNEVMDSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000003306 cortisone group Chemical group 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930194807 paeonin Natural products 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及医药技术领域,发明名称为白芍总苷在制备治疗类风湿关节炎药物中的应用,白芍总苷制备方法为:取白芍,烘干后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,得白芍超微粉;将白芍超微粉上柱层析进行分离,选用XDA‑1B型大孔吸附树脂,柱径高比为1:4~6,上样体积5~7BV,用pH 10~12的氨水溶液7~9BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液9~11BV进行洗脱,弃去洗脱液,再用体积比为8:1~3的乙酸乙酯‑5%冰醋酸溶液9~11BV进行洗脱,流速为1.5~2.5BV·h‑1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得到浸膏,冷冻干燥,粉碎,得到白芍总苷。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种治疗类风湿关节炎的白芍总苷及制备方法。
背景技术
白芍总苷系自白芍饮片提取的总苷。按干燥品计算,含芍药苷(C23H28O11)不得少于40.0%。采用生化提取,可从白芍干燥根中得到芍药苷(paeoniflorin)、羟基芍药苷(hydroxy-paeoniflorin)、芍药花苷(paeonin)、芍药内酯苷(albiflorin)、苯甲酰芍药苷(benzoylpaeoniflorin)等具有生理功效成分的混合物,总称白芍总苷(total glucosidesofpaeonia,TGP)。其中,芍药苷的含量占总甙的90%以上。
发明内容
基于背景技术存在的技术问题,本发明提出了一种治疗类风湿关节炎的白芍总苷及制备方法。
本发明的另一目的是提供该药物的制药用途。
上述发明目的是通过如下方式实现的:
一种治疗类风湿关节炎的白芍总苷,制备方法为:
S1:取白芍,置烘箱内35~40℃烘干4~6h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3000~3400kPa,分级频率为70~90Hz,粉碎时间为45~55min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:4~6,上样体积5~7BV,用pH 10~12的氨水溶液7~9BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液9~11BV进行洗脱,弃去洗脱液,再用体积比为8:1~3的乙酸乙酯-5%冰醋酸溶液9~11BV进行洗脱,流速为1.5~2.5BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得到浸膏,冷冻干燥,粉碎,得到白芍总苷。
所述的治疗类风湿关节炎的白芍总苷,优选制备方法为:
S1:取白芍,置烘箱内37℃烘干5h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3200kPa,分级频率为80Hz,粉碎时间为50min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:5,上样体积6BV,用pH 11的氨水溶液8BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液10BV进行洗脱,弃去洗脱液,再用体积比为8:2的乙酸乙酯-5%冰醋酸溶液10BV进行洗脱,流速为2BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得得到白芍总苷。
白芍总苷在制备治疗类风湿关节炎药物中的应用,白芍总苷制备方法为:
S1:取白芍,置烘箱内35~40℃烘干4~6h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3000~3400kPa,分级频率为70~90Hz,粉碎时间为45~55min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:4~6,上样体积5~7BV,用pH 10~12的氨水溶液7~9BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液9~11BV进行洗脱,弃去洗脱液,再用体积比为8:1~3的乙酸乙酯-5%冰醋酸溶液9~11BV进行洗脱,流速为1.5~2.5BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得到浸膏,冷冻干燥,粉碎,得到白芍总苷。
所述的白芍总苷在制备治疗类风湿关节炎药物中的应用,优选白芍总苷制备方法为:
S1:取白芍,置烘箱内37℃烘干5h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3200kPa,分级频率为80Hz,粉碎时间为50min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:5,上样体积6BV,用pH 11的氨水溶液8BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液10BV进行洗脱,弃去洗脱液,再用体积比为8:2的乙酸乙酯-5%冰醋酸溶液10BV进行洗脱,流速为2BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得得到白芍总苷。
具体实施方式
下面结合具体实施例对本发明作进一步解说。
实施例1:
治疗风湿性关节炎的实验研究
1资料与方法
1.1实验药物与试剂
白芍总苷药物贴膏。
1.2动物
SD大鼠,雌雄各半,体重160~180g,浙江中医药大学医学实验中心提供,饲养于浙江中医药大学医学实验中心,动物饲养于标准条件下,12h明暗交替,(22±2)℃,自由摄食饮水。动物在上述环境中适应性饲养1周后开始实验。
1.3方法
白芍总苷药物贴膏对大鼠佐剂性多发性关节炎具有抑制作用,选用SD大鼠50只分为模型对照组、可的松组、高剂量组、中剂量组、低剂量组,每组10只。用Freund完全佐剂致炎,从致炎前2天给药,方法为:白芍总苷药物贴膏按1.0、2.0、4.0g/kg剂量将白芍总苷药物贴膏按每100克动物体重取0.1ml滴在药棉上包敷致炎足,保持3h,1次/d;以赋形剂为模型对照组,阳性对照选用皮下注射氢化可的松25mg/kg,1次/2d,致炎后第21天各组动物停药,后续观察3d。
1.4观察指标
容积法测量原发性致炎足及继发性对侧足致炎前后体积,计算肿胀度。
2结果
白芍总苷药物贴膏不同剂量组能显著降低致炎后不同时间(3h、7、14、21d)致炎足肿胀度,并能显著降低致炎后不同时间(7、12、18、21d)致炎足肿胀度,分别与模型对照组比较差异有统计学意义(P<0.05)。见表1,表2。
注:与模型对照组比较,aP<0.05
注:与模型对照组比较,aP<0.05
3结论
白芍总苷药物贴膏可确定性抑制大鼠佐剂性关节炎导致局部早期炎症反应和使用后不同时间点肿胀,也可抑制对侧足因迟发性超敏反应诱发的局部肿胀,体现了白芍总苷药物贴膏的祛风除湿、温经止痛和活血通络功效,为临床使用该外用制剂治疗风湿性关节炎提供科学的药效依据。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (4)
1.一种治疗类风湿关节炎的白芍总苷,其特征在于,制备方法为:
S1:取白芍,置烘箱内35~40℃烘干4~6h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3000~3400kPa,分级频率为70~90Hz,粉碎时间为45~55min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:4~6,上样体积5~7BV,用pH10~12的氨水溶液7~9BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液9~11BV进行洗脱,弃去洗脱液,再用体积比为8:1~3的乙酸乙酯-5%冰醋酸溶液9~11BV进行洗脱,流速为1.5~2.5BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得到浸膏,冷冻干燥,粉碎,得到白芍总苷。
2.如权利要求1所述的治疗类风湿关节炎的白芍总苷,其特征在于,制备方法为:
S1:取白芍,置烘箱内37℃烘干5h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3200kPa,分级频率为80Hz,粉碎时间为50min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:5,上样体积6BV,用pH11的氨水溶液8BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液10BV进行洗脱,弃去洗脱液,再用体积比为8:2的乙酸乙酯-5%冰醋酸溶液10BV进行洗脱,流速为2BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得得到白芍总苷。
3.白芍总苷在制备治疗类风湿关节炎药物中的应用,其特征在于,白芍总苷制备方法为:
S1:取白芍,置烘箱内35~40℃烘干4~6h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3000~3400kPa,分级频率为70~90Hz,粉碎时间为45~55min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:4~6,上样体积5~7BV,用pH10~12的氨水溶液7~9BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液9~11BV进行洗脱,弃去洗脱液,再用体积比为8:1~3的乙酸乙酯-5%冰醋酸溶液9~11BV进行洗脱,流速为1.5~2.5BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得到浸膏,冷冻干燥,粉碎,得到白芍总苷。
4.如权利要求3所述的白芍总苷在制备治疗类风湿关节炎药物中的应用,其特征在于,白芍总苷制备方法为:
S1:取白芍,置烘箱内37℃烘干5h后,取干燥后的白芍,采用气流粉碎机进行超微粉碎,气流粉碎机的气流压力为3200kPa,分级频率为80Hz,粉碎时间为50min,得白芍超微粉;
S2:将白芍超微粉上柱层析进行分离上柱层析进行分离,选用XDA-1B型大孔吸附树脂,柱径高比为1:5,上样体积6BV,用pH11的氨水溶液8BV进行洗脱,弃去洗脱液,再用95%的乙醇溶液10BV进行洗脱,弃去洗脱液,再用体积比为8:2的乙酸乙酯-5%冰醋酸溶液10BV进行洗脱,流速为2BV·h-1,收集洗脱液,然后在85℃下蒸馏,除去乙酸乙酯和冰醋酸,再减压浓缩,得得到白芍总苷。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110398135.8A CN113750140A (zh) | 2021-04-14 | 2021-04-14 | 白芍总苷在制备治疗类风湿关节炎药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110398135.8A CN113750140A (zh) | 2021-04-14 | 2021-04-14 | 白芍总苷在制备治疗类风湿关节炎药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113750140A true CN113750140A (zh) | 2021-12-07 |
Family
ID=78786886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110398135.8A Pending CN113750140A (zh) | 2021-04-14 | 2021-04-14 | 白芍总苷在制备治疗类风湿关节炎药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113750140A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1765366A (zh) * | 2004-10-27 | 2006-05-03 | 李红侠 | 白芍总苷片及其制备方法 |
CN102492005A (zh) * | 2011-12-12 | 2012-06-13 | 苏州大学 | 一种芍药苷和白芍苷的制备方法 |
CN108143825A (zh) * | 2018-01-09 | 2018-06-12 | 黑龙江中医药大学 | 一种治疗银屑病的药物及其制备方法与检测方法 |
-
2021
- 2021-04-14 CN CN202110398135.8A patent/CN113750140A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1765366A (zh) * | 2004-10-27 | 2006-05-03 | 李红侠 | 白芍总苷片及其制备方法 |
CN102492005A (zh) * | 2011-12-12 | 2012-06-13 | 苏州大学 | 一种芍药苷和白芍苷的制备方法 |
CN108143825A (zh) * | 2018-01-09 | 2018-06-12 | 黑龙江中医药大学 | 一种治疗银屑病的药物及其制备方法与检测方法 |
Non-Patent Citations (1)
Title |
---|
李钐;王亚楠;刘小宇;张学文;丛培江;: "白芍总苷提取和纯化工艺的研究" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101429254B (zh) | 一种白及多糖及其制备方法和新用途 | |
CN112716989B (zh) | 一种芹菜籽提取物及其制备方法与应用 | |
CN101632827A (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
CN100500196C (zh) | 一种重楼总皂苷的制备方法 | |
CN112870236A (zh) | 一种黄蜀葵花黄酮类有效部位及其制备方法与应用 | |
CN101590086B (zh) | 一种预知子提取物及其制剂与用途 | |
CN100534508C (zh) | 一种制备菝葜有效部位群的方法 | |
CN102872015B (zh) | 一种白药子总生物碱提取物及其制备方法及应用 | |
CN100427136C (zh) | 一种治疗脂肪肝的药物组合物及制备方法和应用 | |
CN110368445B (zh) | 一种治疗银屑病的中药组合物及其制备方法和应用 | |
CN113750140A (zh) | 白芍总苷在制备治疗类风湿关节炎药物中的应用 | |
CN100344299C (zh) | 用于治疗妇女痛经的药物及其制备方法 | |
CN102697932B (zh) | 治疗皮肤瘙痒的药物组合物及质量检测方法 | |
CN102362877B (zh) | 一种雾水葛提取物的应用 | |
CN109248188A (zh) | 一种金雀根提取物的制备方法及其应用 | |
CN1205983C (zh) | 活血止痛胶囊的制备方法 | |
CN115364179B (zh) | 一种降低血尿酸的中药组合物及其制备方法与应用 | |
CN110711207A (zh) | 文王一支笔提取物在制备消化道抗溃疡性结肠炎药物中的应用 | |
CN100457147C (zh) | 一种治疗妇女更年期综合征的中药组合物及制备方法 | |
CN104857107A (zh) | 一种减脂组合物制备方法及减脂剂 | |
CN111905017A (zh) | 一种抗幽门螺旋杆菌的中药组合物及应用 | |
CN114209736B (zh) | 黄花倒水莲总皂苷的应用 | |
CN102406790A (zh) | 一种治疗乳腺增生疾病的中药胶囊及其制备方法 | |
CN103417644B (zh) | 一种黑骨藤复方提取物及其制备方法和用途 | |
CN113694103B (zh) | 不含甘草酸的中药提取物、制备方法、药物制剂及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211207 |
|
RJ01 | Rejection of invention patent application after publication |